Back

Urinary tract infections and sodium-glucose cotransporter 2 inhibitors in heart transplant recipients: a retrospective cohort study

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Pioneering approaches in heart transplantation Heart Transplantation Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Norberto Alonso De La Fuente

Hospital Clinic of Barcelona, Barcelona (Spain)

5 More presentations in this session

Presentation thumbnail
Crystalloid Custodiol based ex vivo perfusion demonstrates comparable efficacy to blood perfusion in a clinically relevant DCD heart transplantation large animal model
Doctor T. Balint (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Characteristics and outcomes of heart transplantation recipients with a history of malignancy: a nationwide population-based cohort study
Professor J. Youn (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
The role of early right ventricular maladaptation to its load in adult heart transplant recipients
Miss J. Mentzel (DE)
Abstract Slides Video
Presentation thumbnail
Pre-transplant right ventricle-to-pulmonary artery uncoupling on echocardiography and risk of early mortality after heart transplantation
Doctor D. Couto-Mallon (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
The interrelatedness of sex and age on survival after heart transplantation
Doctor T. Abdurashidova (Lausanne, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Pioneering approaches in heart transplantation

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Frequency and clinical impact of urinary tract infections in heart failure patients receiving SGLT-2 inhibitor therapy
thumbnail
Congress Presentation
Peri-discharge treatment: ready for the road ahead
thumbnail
Congress Presentation
Cardiovascular diseases and type 2 diabetes mellitus: high heart failure risk and low rate contraindications to SGLT2i

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources